Noida, UP India (PressExposure) October 20, 2011 -- According to our new research report titled, "Global Influenza Vaccine Market Analysis", global seasonal influenza vaccine market has witnessed remarkable changes over the past few years. Vast potential offered by emerging countries along with other important drivers will boost the revenue patterns associated with seasonal influenza vaccines. Backed by key prominent factors, the global seasonal influenza vaccine market will grow at a CAGR of around 8% during 2011-2013.
This report is prepared with the help of paid information and statistics sourced from proprietary databases, primary and secondary research, and detailed analysis by our team of industry experts at RNCOS. Our team of researchers investigated the important development in the global seasonal influenza vaccine market and analyzed their impact in the current scenario. While forecasting, we have also given due consideration to the emerging growth areas in the market, key countries' market performance, and developments, which are essential in determining the prospective growth potentials of the overall sector.
The report which is spread over 55 pages is an outcome of an extensive research and provides detailed analysis on the seasonal influenza vaccination production and coverage, consumption, country-wise industry performance and current scenario in distribution network. The report covers comprehensive information on major marketed brands and growth prospects in the global seasonal influenza market. The report also highlights some of the crucial challenges in the global influenza market and defines the government's role in vaccination process. Overall, the report is likely to provide clients with an in-depth understanding of the global seasonal influenza vaccine market.
Get the Answers You Need to Shape Your Strategy
- For 2011-12 seasons, manufacturers have already begun distributing vaccine lots released by the FDA. What is the share of manufacturers in the US seasonal influenza vaccine production?
- Since the approval of Fluzone Intradermal vaccine by US FDA in May 2011, Sanofi Pasteur is optimistic about the future growth of its seasonal influenza vaccine segment. What is the future outlook of Fluzone and other key seasonal influenza vaccine brands worldwide?
- The existing seasonal influenza vaccine market in China is currently small and under-developed. What is the potential for seasonal influenza vaccine market in the emerging markets?
- It is assumed that the world will witness the production of billion of doses of seasonal influenza vaccines by the end of 2013. What is the overall growth in the production and sales of seasonal influenza vaccines for the period 2010-2013?
To download a free sample of the report, please follow the link below: [http://www.rncos.com/Report/IM356.htm].